Fibralign Corporation

Fibralign Corporation is a Stanford University spin-out produces advanced therapeutic biomedical devices, utilizing its powerful patented Nanoweave® technology. Launched first product - BioBridge® Collagen Matrix for the treatment of secondary lymphedema, a global chronic and disfiguring disease that currently has no cure. BioBridge has received an initial 510(k) clearance, CE mark and KFDA approval and now being used by leading surgeons in 18 countries. MedTech Innovator Award - Overall Winner out of over 800 MedTech startups in this prestigious annual competition StartX Med - Stanford start-up community for healthcare companies (Acceptance rate < 8%) Selected as a UCSF Rosenman Institute Innovator Founding cohort of JLABs @ SSF